Welcome to to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
Yes
No
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

July 30, 2015

Cruinn Diagnostics is proud to launch the new Xprecia Stride analyser in partnership with Siemens Healthcare Diagnostics.

So small, it can fit in your pocket. So accurate, it could go in a lab. The new Xprecia Stride Coagulation Analyzer brings accuracy to the point of care.

Xigduo▼ (Dapagliflozin/Metformin) now Authorised in Ireland for Adults with Type 2 Diabetes

Download PDF                                        Forxiga▼ (dapagliflozin) was launched in Ireland in April 2014 and was the first medicine in the SGLT2 inhibitor class to gain marketing authorisation for the treatment of type 2 diabetes. AstraZeneca Pharmaceuticals (Ireland) Ltd is pleased to announce that Xigduo, which combines dapagliflozin and metformin in one tablet, is now available in […]

New Indication for Xtandi▼ in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer

Download PDF Astellas wish to announce that Xtandi has been approved for patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. Although chemotherapy has been shown to improve overall and progression-free survival in men with metastatic […]

Type 2 Diabetes ADA-EASD Guidelines and 2015 New Updates

Download PDF The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) released a position statement in 2012 on the management of type 2 diabetes mellitus. This was deemed necessary because of the increasing number and variety of pharmacotherapies available to reduce hyperglycaemia, and uncertainty regarding their proper selection and […]

Antihyperglycaemic Therapy in Type 2 Diabetes – List of agents available in Ireland

Download PDF Table 1: Antihyperglycaemic Therapy in Type 2 Diabetes – List of agents available in Ireland Click on image to enlarge

Antihyperglycaemic Therapy in Type 2 Diabetes – Pros and Cons

Download PDF Table 2: Antihyperglycaemic Therapy in Type 2 Diabetes – Pros and Cons Click on image to enlarge Reference: Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes […]

Antihyperglycaemic Therapy in Type 2 Diabetes – General Recommendations

Download PDF Figure A: Antihyperglycaemic Therapy in Type 2 Diabetes – General Recommendations Click on image to enlarge Reference: Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care […]

Antihyperglycaemic Therapy in Type 2 Diabetes – Adapted Recommendations to Avoid Hypoglycaemia or Weight Gain

Download PDF Figures B and C: Antihyperglycaemic Therapy in Type 2 Diabetes – Adapted Recommendations to Avoid Hypoglycaemia or Weight Gain Click on image to enlarge Reference: Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European […]

Ibuprofen: Review confirms small increased cardiovascular risk with daily doses at or above 2,400mg

Non-steroidal anti-inflammatory drugs (NSAIDs) are valuable therapeutic agents in the treatment of pain and inflammation and the risk-benefit profile of these medicines has been closely monitored nationally and at EU level. Previous EU reviews have confirmed that NSAIDs, as a class, are associated with a small increased risk of arterial thromboembolic events (such as myocardial […]

Adverse Reaction Reporting – Reminder

The HPRA greatly appreciates the contribution of busy healthcare professionals in reporting suspected adverse reactions which aids in facilitating the continued surveillance of the safety of medicines. While the time-consuming nature of form-filling and the provision of follow-up is recognised and acknowledged; the collection and evaluation of comprehensive reports is essential to ensure that appropriately […]

Next Page »